Bernstein analyst Eve Burstein raised the firm’s price target on PacBio (PACB) to $1.70 from $1.50 and keeps an Outperform rating on the shares. The firm notes PacBio reported 2Q25 results Thursday, with revenue of $39.8M 9% above consensus estimates of $36.6M. The company narrowed FY25 revenue guidance, but raised the gross margin guide and lowered the OpEx guide, Bernstein adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio Reports Revenue Growth and Strategic Advances
- Positive Long-Term Outlook for Pacific Biosciences Amid Strong Q2 Performance and Strategic Innovations
- PacBio reports Q2 EPS (13c), consensus (17c)
- PACB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PacBio announces results of study published in Nature Methods